Skip to main content

In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa)

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

The in vitro sensitivity of P. falciparum drug-resistant isolates was evaluated in the region of Bobo-Dioulasso during the 1995 and 1996 rainy seasons. Two routinely used antimalarials (chloroquine and quinine) and two new antimalarials (mefloquine and halofantrine) were assessed using 24-hour in vitro cultures with tritiated hypoxanthine and a parasite density <\>> 4,000/mul of blood. The proportion of chloroquine-resistant isolates was 20% in 1995 and 19% in 1996, whilst in 1996, the proportion of isolates resistant to halofantrine was greater than in 1995 (9.6% versus 1%). No significant differences were seen in the mean IC50 values in relation to the susceptibility of chloroquine-resistant or chloroquine-sensitive isolates to mefloquine and halofantrine. In the case of quinine, the mean IC50 values were significantly higher in chloroquine-resistant isolates than in chloroquine-sensitive ones. A significant positive correlation was found between the following IC50 values: chloroquine versus quinine, quinine versus mefloquine and mefloquine versus halofantrine.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Malaria; Plasmodium falciparum; West Africa; chemosensitivity; halofantrine

Document Type: Research Article

Affiliations: 1: Centre Muraz/OCCGE, Malaria Chemoresistance Reference Centre, Parasitology and Entomology Laboratory Bobo-Dioulasso, Burkina Faso 2: Institut de Recherche en Sciences de Ia Sante/CNRST, Ouagadougou, Burkina Faso 3: SmithKline Beecham, Paris, France 4: Department of Paediatrics National Hospital, Bobo-Dioulasso, Burkina Faso

Publication date: 1998-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more